Etidronic acid

SKU: orb1310737

Description

Etidronic acid (HEDP) is a bisphosphonate compound that modulates calcium metabolism by inhibiting pathological calcification and reducing the rate of bone resorption and turnover. It is widely used in osteoporosis research and in vitro studies of mineralization, as well as in vivo models of ectopic bone formation.

Research Area

Cell Biology, Infectious Disease & Virology, Metabolism Research, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 2809-21-4
• MW: 206.03
• Purity: 99.93% (May vary between batches)
• Formula: C₂H₈O₇P₂
• SMILES: C(P(=O)(O)O)(P(=O)(O)O)(C)O
• Target: Apoptosis,Phosphatase,HBV
• Solubility: DMSO:45 mg/mL (218.41 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (9.71 mM)

Bioactivity

• In Vivo:
  Etidronate, when administered s.c. repeatedly at 10 or 40 mg/kg/day, gradually suppresses the adjuvant-induced allodynia In the rats with adjuvant arthritis, as assessed by 10-g von Frey hair. Etidronate (10-40 mg/kg/day) suppresses the adjuvant-induced mechanical allodynia in rat hindpaw. Etidronate (5–10 mg/kg/day) dose-dependently prevents the decrease in bone mineral density (BMD) in the proximal tibia of the arthritic rats. Etidronate inhibits the histidine decarboxylase induction, but not the other inflammatory reactions induced by alendronate. Etidronate (unlike clodronate) also inhibits alendronate-induced BP-line formation in mice (even at 40 mmol/kg). Etidronate (160 mmol/kg) also inhibits the physicochemical changes in the tibia induced by six, weekly injections of alendronate. Etidronate (10 mg/kg) combined with Calcitriol after subtotal nephrectomy (SNx) significantly inhibits thoracic and abdominal aortic calcification 3 weeks after the operation in rats. Etidronate (5 mg/kg or 10 mg/kg) significantly reduces the thoracic and abdominal aortic calcification induced by calcitriol in the renal failure rat. Etidronate (5 mg/kg or 10 mg/kg) also reduces the dysfunction in aortic contraction. Etidronate (5 mg/kg) reverses the reduction in the aortic expression of matrix Gla protein mRNA observed in nephrectomized rats.
  Read more...
• In Vitro:
  Etidronate inhibits directly osteoclastic bone-resorbing activity by pit assay. Etidronate also directly induces apoptosis and disrupts actin rings in osteoclasts.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

protein tyrosine phosphatase(PTP), V-type proton ATPase catalytic subunit, Apoptosis, arterial calcification, osteoporosis, inhibit, Paget's disease, Etidronic acid, Etidronate, HAP, MCF-7, Inhibitor, HEDP, HEDPA

Compound Identifiers

PubChem CID

3305